Addex Pharmaceuticals announced that it has begun Phase I testing of two formulations of ADX10059 and that it will elaborate on ADX10059 development and its pipeline during today's R&D day.

Charlotte Keywood, chief medical officer, said: "This Phase I testing will enable us to identify the optimal formulation to take into Phase IIb and could provide important additional efficacy data for ADX10059 ...